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The Journal of Immunology

TLR-9 and IL-15 Synergy Promotes the In Vitro Clonal
Expansion of Chronic Lymphocytic Leukemia B Cells
Patricia K. A. Mongini,*,† Rashmi Gupta,* Erin Boyle,* Jennifer Nieto,*
Hyunjoo Lee,* Joanna Stein,* Jela Bandovic,‡ Tatjana Stankovic,x Jacqueline Barrientos,{
Jonathan E. Kolitz,*,{,‖ Steven L. Allen,*,{,‖ Kanti Rai,*,{,‖ Charles C. Chu,*,† and
Nicholas Chiorazzi*,†,{,‖
Clinical progression of B cell chronic lymphocytic leukemia (B-CLL) reflects the clone’s Ag receptor (BCR) and involves stromadependent B-CLL growth within lymphoid tissue. Uniformly elevated expression of TLR-9, occasional MYD88 mutations, and
BCR specificity for DNA or Ags physically linked to DNA together suggest that TLR-9 signaling is important in driving B-CLL
growth in patients. Nevertheless, reports of apoptosis after B-CLL exposure to CpG oligodeoxynucleotide (ODN) raised questions
about a central role for TLR-9. Because normal memory B cells proliferate vigorously to ODN+IL-15, a cytokine found in stromal
cells of bone marrow, lymph nodes, and spleen, we examined whether this was true for B-CLL cells. Through a CFSE-based assay
for quantitatively monitoring in vitro clonal proliferation/survival, we show that IL-15 precludes TLR-9–induced apoptosis and
permits significant B-CLL clonal expansion regardless of the clone’s BCR mutation status. A robust response to ODN+IL-15 was
positively linked to presence of chromosomal anomalies (trisomy-12 or ataxia telangiectasia mutated anomaly + del13q14) and
negatively linked to a very high proportion of CD38+ cells within the blood-derived B-CLL population. Furthermore, a clone’s
intrinsic potential for in vitro growth correlated directly with doubling time in blood, in the case of B-CLL with Ig H chain V
region–unmutated BCR and <30% CD38+ cells in blood. Finally, in vitro high-proliferator status was statistically linked to
diminished patient survival. These findings, together with immunohistochemical evidence of apoptotic cells and IL-15–producing
cells proximal to B-CLL pseudofollicles in patient spleens, suggest that collaborative ODN and IL-15 signaling may promote
in vivo B-CLL growth. The Journal of Immunology, 2015, 195: 901–923.

B

cell chronic lymphocytic leukemia (B-CLL) is the most
prevalent adult leukemia in the United States, Europe, and
Australia, and it targets mainly elderly adults (1). Its

*The Feinstein Institute for Medical Research, North Shore–Long Island Jewish
Health System, Manhasset, NY 11030; †Department of Molecular Medicine, Hofstra
North Shore–LIJ School of Medicine, Hempstead, NY 11549; ‡Department of
Pathology, North Shore University Hospital–Long Island Jewish Medical Center,
Manhasset, NY 11030; xSchool of Cancer Sciences, University of Birmingham,
Birmingham B15 2TT, United Kingdom; {Department of Medicine, North Shore
University Hospital–Long Island Jewish Medical Center, Manhasset, NY; and ‖Department of Medicine, Hofstra North Shore–LIJ School of Medicine, Hempstead, NY
Received for publication December 22, 2014. Accepted for publication May 30,
2015.
This work was supported by the National Cancer Institute, National Institutes of
Health (Grant CA081554 to N.C.); National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (Grant AR061653 to P.K.A.M.);
philanthropic contributions to the Center for Chronic Lymphocytic Leukemia Research from The Karches Foundation, the Marks Foundation, the Jerome Levy Foundation, the Leon Levy Foundation, and the Frank and Muriel Feinberg Foundation;
and research support from Dr. Betty Diamond (the Center for Autoimmunity and
Musculoskeletal Diseases, Manhasset, NY).
Address correspondence and reprint requests to Dr. Patricia K.A. Mongini, The
Feinstein Institute for Medical Research, Center for Autoimmunity and Musculoskeletal Diseases, Laboratory of B Cell Biology, 350 Community Drive, Manhasset, NY
11030. E-mail address: pmongini@nshs.edu
The online version of this article contains supplemental material.
Abbreviations used in this article: ATM, ataxia telangiectasia mutated; B-CLL, B cell
chronic lymphocytic leukemia; DIV, divided; FDC, follicular dendritic cell; FISH,
fluorescence in situ hybridization; FSC, forward light scatter; GR, growth rate; IGHV,
Ig H chain V region; M-CLL, IGHV mutated B-CLL; ODN, oligodeoxynucleotide;
OS, overall survival; PB, peripheral blood; TFT, time-to-first treatment; TRI-12,
trisomy-12; U-CLL, IGHV unmutated B-CLL.
This article is distributed under The American Association of Immunologists, Inc.,
Reuse Terms and Conditions for Author Choice articles.
Copyright Ó 2015 by The American Association of Immunologists, Inc. 0022-1767/15/$25.00
www.jimmunol.org/cgi/doi/10.4049/jimmunol.1403189

incidence will undoubtedly increase as the population aged .60 y
grows in future decades. Although recent therapeutic advances
have notably improved the outcome for many patients (2, 3),
B-CLL remains incurable for the following reasons: 1) diverse sites
for B-CLL compartmentalization in the body, 2) important ancillary effects of the stromal environment, 3) mutagenic mechanisms
for generating variants able to escape therapy, and 4) a possible
leukemic stem cell compartment that remains unaffected upon
depletion of mature leukemic cells. Thus, continued insights are
needed regarding how to control this disorder.
A major advance in understanding B-CLL biology was the definition of a B-CLL proliferative component (4, 5), despite blood
manifestation as small, relatively quiescent cells. Proliferative foci,
often termed pseudofollicles or proliferation centers, are typically
found within secondary lymphoid tissue and the bone marrow (6, 7).
Growth not only expands leukemic cell numbers, but additionally
introduces genetic instability through diverse routes, including
division-related upregulation of activation-induced cytosine deaminase (8, 9).
Pseudofollicle growth depends on features of the leukemic
clone, as well as stimuli within the leukemic milieu (10, 11). Ag
receptors (BCR) expressed by the leukemic clone appear to play
a critical role as suggested by the strong linkage between leukemia in vivo growth and Ig H chain V region (IGHV) mutation
status (4, 5), and by the recent effectiveness of Btk inhibitors in
treating B-CLL (2). Although the mechanism(s) whereby BCR
fosters B-CLL growth remain poorly understood (12–16), the
generally modest in vitro B-CLL proliferation elicited by most
BCR cross-linking agents (17) suggests that the BCR of many
B-CLL are anergic (18) and that costimuli from other receptors
are important.
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However, the concept that BCR might function more in mediating the internalization of immunostimulatory CpG DNA, the
ligand for intracellular TLR9, has several lines of support. The
BCRs of many B-CLL, particularly the IGHV unmutated B-CLL
(U-CLL) subgroup, bind to intracellular proteins expressed on
apoptotic cell membranes (19–21) that coexpress DNA (19, 22).
Furthermore, numerous B-CLL BCRs show specificity for DNA
(23–25), and at least two stereotyped BCRs of the IGHV mutated
B-CLL (M-CLL) subgroup, one specific for IgG (rheumatoid
factor specificity) (26, 27) and the other specific for b-(1, 6)glucan of yeasts and filamentous fungi (28), engage Ags physically linked to CpG DNA (29, 30). All of these could elicit intracellular TLR-9 signaling upon BCR internalization of Ag (31,
32). Providing additional support for a role of BCR and TLR-9
signaling in driving B-CLL pseudofollicle growth is the evidence
that malignant cells from lymph nodes express more BCR- and
TLR-pathway genes than those taken from blood (11). Furthermore, a number of B-CLL bear function-enhancing mutations in
MYD88, a critical protein in the TLR-9 signaling pathway (33).
B-CLL progression in TCL-transgenic mice is also accelerated
when SIGIRR (TIR8), a known negative regulator of TLR-9 signaling, is deleted (34).
Interest in a possible B-CLL dependency on TLR-9 signals led
several laboratories to investigate whether in vitro exposure to CpG
oligodeoxynucleotide (ODN) triggers blood-derived B-CLL to
proliferate (35–37). Unexpectedly, although ODN did trigger increased [3H]thymidine uptake in a subset of B-CLL (those characterized by stronger activation of Akt, ERK, JNK, p38 MAPK,
and NF-kB) (35, 36), another subset succumbed to ODN-induced
apoptosis (37, 38). This was not linked to TLR-9 expression because all B-CLL express relatively high TLR-9 (35, 39). Rather, as
recently reviewed (40), B-CLL cell diversity in TLR-9 responsiveness correlates with IGHV mutation status, with M-CLL
clones showing significant ODN-induced apoptosis.
The stromal environment plays key roles in promoting B-CLL
growth (10, 11), and it is warranted to consider which costimuli
might make TLR-9 signals uniformly stimulatory for all B-CLL.
Signals from nearby activated CD4+ T cells might be important
given earlier evidence that the B-CLL response to ODN is boosted
with CD40L and IL-2 (36, 39, 41). Also important may be in vivo
signals from lymphoid tissue stromal cells, follicular dendritic
cells (FDCs), and endothelial cells, each of which has been reported to affect B-CLL survival/growth under other conditions
(reviewed in Ref. 42).
IL-15, an inflammatory cytokine produced by each of the earlier
mentioned nonlymphoid cells (43–46), is a plausible candidate for
promoting TLR-9–triggered growth of B-CLL. Although the cytokine is best known for its major effects on the development/
growth/survival of NK cells, CD8 T cells, and intraepithelial g/d
T cells (47, 48), human memory B cells exhibit vigorous in vitro
proliferation upon exposure to both IL-15 and CpG DNA (49).
Evidence that B-CLL are more homologous to memory B cells
than naive B cells in gene expression arrays (50) suggests that
B-CLL might exhibit a similar response. This possibility is heightened by past findings that B-CLL cells express all three chains of
the trimeric IL-15R: high-affinity IL-15–specific IL-15Ra, loweraffinity IL-2/15Rb (CD122), and common g-chain, gc (CD132)
(51, 52); furthermore, IL-15 increases B-CLL survival and proliferation in response to either CD40L (52) or Staphylococcus
aureus Cowan strain 1 cells (53). One particularly compelling
reason for considering that IL-15 might foster B-CLL growth
within patients is the recent finding that IL-15 is constitutively
produced by stromal cells within bone marrow, spleen, and lymph
nodes (43–45), which are sites for B-CLL growth in patients.

IL-15 AND TLR-9 INDUCED B-CLL PROLIFERATION
Furthermore, like the incidence of B-CLL, the levels of stromal
cell–expressed IL-15 increase with age in both mouse spleens
(44) and human bone marrow (54).
Taken together, these findings pose the question of whether IL15 might boost the response of B-CLL to TLR-9 signals and drive
B-CLL clonal expansion. In this study, we investigated this
question by monitoring the growth and survival of CFSE-labeled
B-CLL cells with approaches that have yielded important insights
concerning the clonal growth and activation-induced death of
normal human B lymphocytes (55–57). We found that B-CLL
populations almost without exception show heightened in vitro
viability and clonal expansion upon exposure to both ODN and
IL-15. Nonetheless, because diversity between individual B-CLL
populations in the degree of survival and/or cycling was apparent,
we explored whether these differences associate with IGHV U
versus M status, with the expression of chromosomal anomalies
commonly linked to B-CLL, and with patient clinical outcome.
Finally, we undertook an immunohistological study to discern
whether IL-15–producing cells are present within and proximal to
B-CLL pseudofollicles in patient spleens.

Materials and Methods
Ethics statement
These studies were approved by the Institutional Review Board of the North
Shore–Long Island Jewish Health System (08-202A). Written, informed
consent was obtained from CLL-bearing patients and normal subjects in
accordance with the Declaration of Helsinki before blood collection.

CLL patient samples and characterization
B-CLL specimens for in vitro study were obtained, in nearly all cases (39/
40), from patient peripheral blood (PB); in one case, B-CLL cells were
obtained from lymphoid tissue after splenectomy in the course of treatment.
Most samples were obtained from B-CLL patients prior to commencing
chemotherapy or treatment with biologicals (33/40 cases). For the 7 B-CLL
cases that received prior treatment, the interval between therapy and sample
isolation is indicated in Table I. Clinical information, laboratory data including results from fluorescence in situ hybridization (FISH) analyses
for common B-CLL chromosomal anomalies, and IGHV DNA sequence
mutation status were available for these patients (Table I). The cases were
either not complex, being solely del13q14 or del11q22 or trisomy-12 (TRI12), or when they were complex involved primarily del11q22 + del13q14;
none involved del17p (p53 deletion). In this study, the term B-CLL clone is
used to connote a CD19+/CD5+ B-CLL population expressing a uniform
IGHV sequence. This does not exclude the presence of subclones with
other differing characteristics. Indeed, heterogeneity in the proportion of
leukemic PB cells displaying FISH genetic anomalies (Table I) shows that
subclones were present at the time of sampling.

Ataxia telangiectasia mutated mutation status
In a selected group of B-CLL (9/40), the entire ataxia telangiectasia mutated
(ATM) coding region, consisting of 62 exons, was screened using HPLC.
Sequence changes were considered to be: 1) truncating mutations, if they
were predicted to cause premature termination of the protein or small inframe deletion; or 2) missense mutations, if they were either reported in
ATM patients or predicted to cause an amino acid substitution in the
residue located within the region encoding the functional domain of the
ATM protein and/or conserved between human and mouse and not observed in 200 alleles of healthy controls. This method was described in an
earlier publication (58).

B-CLL cell isolation
B-CLL cells from each patient’s PB, or in some cases from normal subjects, were isolated by negative selection using RosetteSep Human B Cell
Enrichment Cocktail (Stemcell Technologies, Vancouver, BC). Whole PB
was incubated with the mixture, then diluted with 2% FBS (Atlanta Biologicals, Flowery Branch, GA) in PBS and centrifuged over RosetteSep
DM-L Density Medium (Stemcell Technologies). When 31 B-CLL PB
specimens initially purified by this technique were tested for purity by the
Center for CLL Research, it was determined that of the events collected,
81 6 10% was in the lymphocyte scatter gate and 92.7 6 9% of the latter
was CD19+/CD5+. Based on scatter, some of the nonlymphocytes were

The Journal of Immunology
contaminating RBCs; others may have been aggregates. These were not
apparent when isolated B-CLL B cell preparations were frozen (2150˚C),
defrosted, and collected at the interface after Ficoll-Hypaque density
centrifugation. Ten of the frozen B-CLL B cell preparations evaluated
in this study were subjected to immunofluorescent Ab staining after
defrosting, and the following profile was noted: CD19/CD5+ = 92 6 5%
(mean 6 SD); CD3+ = ,1%; CD14 = ,1%; CD16 = ,1%. Minor contamination with CD19+, CD52 normal B cells was on occasion evident but
always ,10%; only in one case (CLL1300) was CD3 (8%) and CD14
(2%) contamination seen. Isolation of a single spleen-derived B-CLL
(CLL967) involved Ficoll-Hypaque density centrifugation of a singlecell suspension of splenocytes before B cell negative selection with
magnetic beads and freezing; defrosted cells were subsequently centrifuged through a 40/50/55/75% Percoll density gradient to enrich for uniformly small lymphocytes at the 55/75% interface; when analyzed by flow
cytometry, these were 98% CD19+CD5+, 1% CD3+, and 1% negative for
B/T markers. Defrosted samples were routinely subjected to FicollHypaque centrifugation to eliminate any dying/dead cells and to ensure
that all studies began with uniformly viable B-CLL. Viability assessments
(trypan blue dye exclusion) of defrosted PB-derived B-CLL B cells made
prior to Ficoll-Hypaque centrifugation in a random group of B-CLL (n =
10) showed viability values ranging from 74 to 99% (92 6 3% = mean 6
SEM). In the total samples studied (n = 40), the average post-Ficoll recovery of viable B-CLL cells from those initially frozen was 57 6 5%
(mean 6 SEM). Frozen B-CLL specimens that routinely showed poor
recovery/viability were excluded.

In vitro culture conditions for B-CLL replication
CFSE-labeled B-CLL cells were cultured in an enriched medium used for
normal B cell replication in long-term cultures (55) with added insulin/
transferrin/selenium supplement (catalog no. 17-8387; BioWhittaker).
Notably, this medium contains the reducing agent, 2-ME (5 3 1025 M).
The latter replaces an important function of bone marrow stromal cells in
converting cystine to cysteine, which is needed for B-CLL uptake and use
in the glutathione synthesis needed for retained viability (59). To minimize
interexperimental differences, we freshly prepared medium for each
experiment using stock additives whose expiration date was carefully
monitored and, in the case of FCS and the insulin/transferrin/selenium
supplement, kept frozen in aliquots until use. Cultures were routinely
established in 96-well plates (Falcon; Costar) at 105 cells per 200-ml
volume with triplicates for each culture condition. Recombinant human IL15 (R&D Systems) and CpG DNA TLR-9 ligand (ODN-2006; Invivogen)
(frozen in aliquots until use) were added at final culture concentrations
of 15 ng/ml and 0.2 mM (1.5 mg/ml), respectively. In designated cultures,
the pan-caspase inhibitor, Z-VAD-FMK (40 mM final; Sigma-Aldrich,
St. Louis, MO), or DMSO vehicle was added.

Assays for B-CLL replication and viability
Previously described methods for quantifying the growth/viability of
CFSE-labeled lymphoblasts within in vitro–activated normal human B
cell cultures were used (55–57) and are outlined in schematic form in
Supplemental Fig. 1. When the absolute number of viable lymphoblasts
present in culture was quantified, cultures were pulsed with a known
number of CountBright absolute counting beads (Molecular Probes, Life
Technologies) just before harvesting (56, 57). For cell harvest, culture
plates were routinely placed on wet ice for 10 min to facilitate detachment
of activated B-CLL from the culture wells; without this step, B-CLL recovery in ODN+IL-15 cultures was often compromised because of cell
adhesion to wells. Cells (and accompanying beads) were harvested and
washed through cold PBS before immediate fixation in 1.5% formaldehyde
for subsequent analysis by flow cytometry (FACSCalibur or FACS-Verse
with CellQuest or FlowJo 7.6.1 data analysis software). Selection of intact
cells (viable + apoptotic) as opposed to debris was based on a consistent
threshold set in each experiment based on the forward light scatter (FSC)
intensity of the standardizing CellQuant beads (note that the side scatter of
the beads is significantly greater than that of B-CLL cells, enabling clear
segregation). Quantification of beads is performed on the basis of their
high allophycocyanin fluorescence. Gates for delineating undivided
B-CLL cells were established on the basis of CFSE intensity of B-CLL from
cultures supplemented with IL-15 only, in which the majority of cells do
not replicate at the used dose of IL-15; gates for other divisions were based
both upon a 50% reduction in CFSE fluorescence upon each successive
division and visual inspection of CFSE peaks from ODN+IL-15–stimulated cultures. Percent viability of activated B-CLL within each division
subset was discerned by assessing CFSE-gated cells on the basis of light
scatter (55–57) or exclusion of Fixable Viability Stain 450 (FVS450; BD
Biosciences). As described earlier for studies on activated normal B
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lymphoblasts (55, 57, 60), percentage viability values of ODN-activated
B-CLL obtained through light scatter and viability dye exclusion are
virtually identical (see Supplemental Fig. 1). Nonetheless, viable dye
exclusion assays are more reliable when small, relatively quiescent
B-CLL cells cultured with medium or IL-15 alone are monitored.

Two-color flow-cytometric assays for assessing CD38
expression as a function of cell division
CFSE-labeled cultures were harvested in cold PBS, resuspended in PBS +
1% BSA + 0.1% sodium azide assay buffer, surface stained with allophycocyanin anti-human CD38 or allophycocyanin-IgG control (Becton
Dickinson), fixed with 1% paraformaldehyde, and analyzed by flow
cytometry using methods described earlier (55).

Immunohistochemical analyses
Formalin-fixed, paraffin-embedded sections from human B-CLL spleens,
removed for therapeutic reasons, were serially sliced into 4- to 6-mM
sections and placed onto glass slides. Similarly prepared sections from two
normal human spleens were obtained. One spleen had been determined by
pathologists to have only passive congestion after removal from a patient
with pancreatic carcinoma; the other was a spleen from a deidentified 30-yold normal man, sectioned and commercially distributed by US Biomax
(HuFPT082; Rockville, MD). All spleen tissue sections were deparaffinized and subjected to Ag retrieval in a heated pressure cooker (125˚C, 3
min) followed by blocking for endogenous peroxidases with 3% H2O2 in
methanol. The tissues were preblocked with 25% normal serum matching
the secondary detection Ab’s species and further subjected to avidin/biotin
blocking (kit from Vector Labs) before incubation at 4˚C overnight in
a humidified chamber with primary Ab: goat anti-human IL-15 (AF 315;
R&D Systems), mouse anti-human Pax-5 (IS650, clone DAK; Dako), or
mouse anti-human Ki-67 (N1633, clone Mib 1; Dako) at the recommended
dilutions along with appropriate isotype controls. Sections from CLL-967
spleen were additionally exposed to mouse IgM anti-human FDC mAb
(clone CNA.42; 1:500; Affymetrix; eBioscience) or rabbit IgG mAb specific for active (cleaved) caspase-3 (Asp175; 1:200; Cell Signaling 9664), or
negative controls. The following secondary biotin-conjugated, affinitypurified F(ab9)2 reagents were used for Ig detection (each commercially
absorbed against human serum proteins): donkey anti-goat IgG (code 705066-147; Jackson Immunoresearch), donkey anti-rabbit IgG (code 711066-152; Jackson Immunoresearch), horse anti-mouse IgG (BA-2000;
Vector Laboratories), or goat anti-mouse IgM (m-chain–specific; code
115-066-075; Jackson Immunoresearch). Each secondary Ab was followed
by treatment with Vectastain ABC kit (Elite, pk6100-standard; Vector
Laboratories) and detection achieved with the ImmPACT DAB Peroxidase
substrate kit (Sk 4105; Vector laboratories). The tissues were counterstained with hematoxylin, dehydrated, and mounted using Vectamount
permanent mounting media (H5000; Vector Laboratories). Most images
were photographed at final magnifications of 1003, 2003, or 6003 (the
latter with a 603/1.25 Oil Iris ‘/0.17) using an Olympus BX40 phase-contrast
microscope and Olympus DP20 camera.

Determinations of B-CLL in vivo growth rate
Values for B-CLL growth rate (GR; number of doublings per month) were
determined from the calculated time for doubling of lymphocyte counts
within PB using an online doubling time/GR calculator based on exponential regression (Roth V. 2006 http://www.doubling-time.com/compute.
php). GR determinations were made for CLL cases in which sequential
values for absolute lymphocyte count (ALC) in blood were available (36/
40). ALCs were obtained during a period that included the time blood was
acquired for these functional studies, in all but two cases, over a time range
of 1 to 80 mo (mean 6 SD = 27 6 23 mo). The incidence of ALC
measurements for doubling time/GR determinations was as follows: 7
CLLs based on 2 ALCs, 18 based on 3, 5 based on 4, 4 based on 5, 1 based
on 6, and 1 based on 10.
Kaplan–Meier analysis was used to test whether clinical progression,
defined as time-to-first treatment (TFT), was a function of several
parameters in ODN+IL-15–stimulated cultures: 1) viability in the divided
(DIV) blasts (#75% versus .75% viable); 2) replication (#75% versus
.75% of the total viable cells as DIV; and 3) extended replication (#50
versus .50% of the total viable DIV cells representing .2 DIV). In each
of these cases, the cohort was subdivided so that approximately equal
numbers of clones were represented in each category. In addition, TFT
and overall survival (OS) were monitored as a function of extended
replication (#50 versus .50% of the total viable cells representing .2
DIV). Finally, TFT was monitored as a function of the IGHV mutation and
del11q22 status of the B-CLL clones. Log-rank statistical evaluation was
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used to determine significance of any differences noted in each pair
of plots.

Other statistics
Box plots were used to show summed statistics for various cohorts of
B-CLL studied. In box plots, the upper part of the box represents the third
quartile (75th percentile) and the lower part of the box the first quartile (25th
percentile); upper and lower whiskers represent error bars for the 10th and
90th percentiles, respectively; outliers are shown as individual points.
Furthermore, the mean and median values for the grouped data are shown by
solid and dashed lines, respectively, within each box. In nontreatmentrelated comparisons, when the samples were from the same B-CLL, the
nonparametric test, Wilcoxon signed rank test for matched pairs, was used
to determine whether medians of the differences between measurements
differed significantly. When samples were independent, the nonparametric
test, Wilcoxon rank sum test, was used to compare pairwise group differences, and the Kruskal–Wallis test was used when groups were $3.
These tests were used because they do not assume the differences in the
outcome are normally distributed. For the correlation analyses, both the
Pearson correlation coefficients and the Spearman rank coefficients were
calculated. The Pearson correlation coefficients measure the strength and
direction of the linear relationship between the two variables, whereas the
Spearman correlation is used when one or both of the variables are not
assumed to be normally distributed. For the analyses evaluating significance in all pairwise FISH-determined genetic anomaly groups, the nonparametric Wilcoxon rank sum test was used with two-sided Monte Carlo
estimation of the exact p values. Results are considered statistically significant if p , 0.05 on the two-sided tests, with the exception of the
pairwise comparisons between responses of the various FISH subgroups in
which Bonferroni correction methods for adjusting the p value for multiple
comparisons was used (statistical significance if p , 0.005). Analyses
were carried out in SAS Version 9.3 (Cary, NC). SigmaPlot 12.0 was used
to determine linear regression plots and respective significance values for
comparisons of B-CLL in vivo and in vitro growth.

Results
Effect of IL-15 on B-CLL viability and growth in
ODN-stimulated B-CLL cultures
We initiated these studies with the hypothesis that B-CLL growth
responses to CpG DNA will be significantly augmented by the
inflammation-linked cytokine, IL-15. Purified B cells from the PB
of 12 B-CLL patients were CFSE labeled and cultured (6–7 d) in
medium supplemented with either IL-15 or ODN, or both, to test
this hypothesis. The number of division cycles and the viability
during successive divisions were determined, as described in
Supplemental Fig. 1 and detailed elsewhere (55, 57). Assessing
the impact of division on viability was deemed important given
earlier evidence that normal cycling B lymphoblasts are prone to
p53-regulated death during responses to T cell–independent stimuli
(55, 57).
Fig. 1A–D shows representative flow-cytometric data from
cultures of four leukemic B-CLL clones: two with unmutated and
two with mutated IGHVs (U-CLL-430/U-CLL-996 and M-CLL1380/M-CLL-1031, respectively). We found that B-CLL exposed
to IL-15 alone (15 ng/ml) remained relatively small (low FSC;
Fig. 1A, 1B) and generally did not proliferate, as illustrated by the
single major peak in the CFSE histograms (Fig. 1A–D, lower left).
At this dose of IL-15, there was only a slight improvement in
viability above cells in medium alone (111 6 12%, mean 6 SD in
n = 10 experiments using V450 dye exclusion to monitor viability;
see also Fig. 1E). Stimulation by ODN alone augmented B-CLL
size (Fig. 1A, 1B), but only slightly increased division over the
span of 6–7 d (Fig. 1A–D, lower middle histograms). Consistent
with earlier reports, the viability of U-CLL and M-CLL cultures
after ODN stimulation was quite different (U-CLL = 46–57%
versus M-CLL = 15–17%; Fig. 1A–D, upper middle dot plots).
ODN-induced death in M-CLL cultures was blocked if the pancaspase inhibitor, Z-VAD-FMK, was present (Fig. 1E), reflecting
ODN-induced apoptotic death (38). Importantly, when ODN-
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exposed U-CLL or M-CLL concomitantly received IL-15 signals, culture viability increased (Fig. 1A–D, upper right dot plots).
Furthermore, clonal expansion was clearly evident (Fig. 1A–D,
lower right histograms). Other experiments show that IL-15 doses
as low as 1 ng/ml can significantly augment ODN-triggered
B-CLL division (data not shown).
A summary of IL-15 effects on the ODN-stimulated responses of
six M-CLL and six U-CLL is shown in Fig. 1F (top row). Concomitant IL-15 signaling significantly augmented survival in both
noncycling and cycling M-CLL (p = 0.03 for both). This prosurvival effect appeared to fully eliminate the striking difference
between U-CLL and M-CLL viability seen in the nondivided
fraction when IL-15 was absent (p 5 0.008). Furthermore, IL-15
significantly boosted the proportion of viable cells evidencing
division, both in M-CLL and in U-CLL cultures (p = 0.03 for
both). Additional evidence of the division-potentiating effects of
this cytokine is shown in Fig. 1G (top panels), where data are
represented as the absolute yield of viable cells per culture well
(determined by pulsing cultures with standardizing beads at the
time of harvest). Exposure to IL-15 at the time of ODN stimulation increased the yield of DIV B-CLL lymphoblasts from 14-fold
to 56-fold in the case of U-CLL 770 and M-CLL 922, respectively.
An example of the effect of ODN 6 IL-15 signaling on normal
human B cells (27% positive for memory marker, CD27) is presented in Fig. 1F (bottom row) and 1G (bottom panel). This experiment confirms that IL-15 can significantly augment ODNinduced B cell growth (49, 61), and additionally shows that IL15 boosts the survival of DIV normal B cell blasts, as was noted
earlier for U-CLL and M-CLL. Normal B cell responses are more
representative of U-CLL than M-CLL: ODN signaling alone enhanced B cell survival above that seen in IL-15–only cultures (or
medium-only cultures; data not shown). Contrasting with the
generally high viability of undivided CLL cells (exception is
ODN-treated M-CLL) was the low viability of undivided normal
B cells (,30% viable after 6 d of culture; Fig. 1F). This difference
likely reflects the elevated baseline expression of several prosurvival molecules in B-CLL (62).
Phase microscopic evidence of the cellular changes induced by
ODN 6 IL-15 is presented in Fig. 2. M-CLL cultures receiving
the TLR-9 stimulus alone show substantially more cell shrinkage
and debris formation (Fig. 2B) than comparably stimulated cultures of U-CLL (Fig. 2E) or PB B cells (Fig. 2H). In contrast,
when ODN and IL-15 are jointly present, both U-CLL and
M-CLL cultures show significant cell enlargement and aggregate
formation (Fig. 2C, 2F). The clustering was comparable with or
greater than that seen in normal B cell cultures (Fig. 2G–I). Differences were noted between B-CLL clones in the degree of
clustering, but the reason for this is unexplored.
Taken together, our study confirms earlier findings that IGHVmutated B-CLL are prone to apoptosis upon receiving TLR-9
stimuli alone (37, 38, 40), and importantly shows for the first
time, to our knowledge, that additional IL-15 signaling not only
abrogates this outcome but can foster significant clonal expansion
within both M-CLL and U-CLL, as earlier reported for normal
memory B cells (49).
Immunohistochemical evidence for IL-15–expressing cells and
apoptotic cells/debris within B-CLL–infiltrated human spleens
with pseudofollicles
The recent evidence that the IL-15 gene is constitutively active
within several nonlymphoid cell lineages (macrophages and stromal, endothelial, and dendritic cells) in normal mouse primary
and secondary lymphoid tissues (44) suggests that IL-15 should be
present in known sites of human B-CLL clonal expansion. This
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FIGURE 1. ODN+IL-15 signaling induces M-CLL and U-CLL clonal expansion. (A–D) Plots showing viability gating and CFSE division histograms
(for viable cells) in IGHV U-CLL 430 and 996 (A and C) and IGHV M-CLL 693 and 1031 (B and D) clones at day 6 after culture with IL-15 alone, ODN
alone, or both ODN+IL-15. Plots in (A) and (B) reveal the presence of calibration beads (upper left gate) added for quantification of absolute yield of
viable cells (as for G) and as a means of discerning the threshold between debris and intact (via or dead) cells (see Supplemental Fig. 1). (E) Pan-caspase
inhibitor (Z-VAD-FMK) inhibits ODN-induced death in M-CLL, consistent with an apoptotic mechanism. Immediately after B-CLL culture with the
indicated stimuli, sets of parallel cultures were pulsed with Z-VAD-FMK (40 mM) or vehicle control (DMSO). Cells were harvested at day 3, stained with
viable cell exclusion Dye 450, and fixed and analyzed by flow cytometry for viable/dead cells. Data are expressed as mean 6 SEM values of triplicate
cultures. Asterisks indicate that differences between DMSO versus Z-VAD–treated cultures were statistically significant (p , 0.01) on the basis of a twosided, unpaired Student t test. (F, top panels) Pooled analysis (mean 6 SD) of experiments with six IGHV U and six IGHV M B-CLL clones showing (top
left panel) % viability in undivided gate of total viable+apoptotic CFSE-labeled cells, (top middle panel) % viability in DIV gate of total viable+apoptotic
cells, and (top right panel) % DIV cells within all gated viable cells after 6–7 d of culture with stimulants shown. The p values for two-sided
significance are indicated. Bottom panels, Similar analysis of the ODN 6 IL-15 responses of purified normal human PB B cells (Figure legend continues)
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FIGURE 2. Photomicrographs of M-CLL 1031 (A–C), U-CLL 996 (D–F), and normal B cells from PB (G–I) after 6 d of culture in IL-15 alone (A, D, and
G), ODN alone (B, E, and H), or both ODN+IL-15 (C, F, and I). Culture of M-CLL with ODN alone (B) typically induces prominent loss of cell volume and
formation of debris, not seen with similarly cultured U-CLL (E) or normal B cells (F). Stimulation with ODN+IL-15 induces notable cell enlargement,
larger clump formation, and significant cell proliferation in M-CLL (C), U-CLL (F), and normal B cell (I) cultures. Photographs were taken at original
magnification 3200 using an Olympus BX40 phase-contrast microscope equipped with an Olympus DP20 camera.

possibility is further supported by reports of IL-15 protein in
isolated myofibroblasts from normal human spleen (63), FDCs
within human tonsils (43), and stromal cells within human bone
marrow (45, 64). Nonetheless, there is no direct evidence showing
that IL-15–producing cells are present within B-CLL–infiltrated
tissues harboring pseudofollicles, and it remains possible that
B-CLL infiltration might suppress IL-15 production in these sites,
perhaps as a means of preventing the expansion of cytotoxic
T cells and NK cells that rely on this cytokine (47, 48).
To discern the extent that IL-15–producing cells localize
proximal to areas of B-CLL replication in patient lymphoid tissue,
we undertook an immunohistological study of spleen sections
from three B-CLL patients subjected to therapeutic splenectomy.
Fig. 3 shows the results from staining sequential slices of each
spleen for IL-15, the B cell–specific transcription factor, PAX-5,
and the proliferation marker, Ki-67. The white pulp of spleens
infiltrated with M-CLL 967 and U-CLL 1369 was hyperplastic
and possessed PAX-5+ pseudofollicles (Fig. 3A, 3F) with numerous Ki-67+ proliferating cells (Fig. 3B, 3G). The sections of
spleen with U-CLL 852 had less defined pseudofollicles, but
Ki-67+ proliferating cells were scattered uniformly throughout
(Fig. 3O). In each of these spleens, cells expressing cytoplasmic
IL-15 were prevalent throughout the white pulp, as represented by
Fig. 3C and 3E (M-CLL967), Fig. 3H and 3L (U-CLL 1369), and
Fig. 3P (U-CLL 852). Although IL-15+ cells could be found
within the Ki-67+ zones of many pseudofollicles (Fig. 3B, 3C, 3G,

3H, 3K, 3L), others were present at the margins of pseudofollicles.
From the higher magnification of the CLL-967–infiltrated spleen
(Fig. 3E), it can be discerned that some IL-15+ cells possess the
elongated processes characteristic of FDCs or possibly reticular
stromal cells. In addition, in some IL-15–stained cells, the cytokine appears to be localized in small vesicles or in a perinuclear
pattern, both of which have been reported (65, 66).
Because of reports that FDCs within tonsils produce IL-15 (43),
we investigated whether IL-15+ cells colocalized with FDCs using
sequential tissue slices and a staining mAb specific for human
FDCs in fixed, paraffin-embedded tissues, CNA.42 (67) (Fig. 4).
From this analysis, we concluded that both IL-15–producing cells
and FDCs are present in the same PAX-5+, Ki-67+ pseudofollicles
(Fig. 4A–D). Nonetheless, a definitive conclusion that splenic
FDCs are IL-15 producers could not be made with this approach.
(Two-color fluorescent staining was precluded because of a very
high RBC fluorescence background in the available B-CLL sections.)
IL-15–producing cells are also found within normal human
spleens, as evidenced by the images in Fig. 5. These represent
2003 and 6003 photographs of IL-15–stained spleen sections from a normal 30-y-old man (see Materials and Methods)
(Fig. 5A) and from a patient with pancreatic cancer (Fig. 5B). The
latter spleen was determined to be normal, with the exception of
passive congestion, upon evaluation by a clinical pathology laboratory. Both of these spleens had IL-15–stained cells scattered

(determined to be 98% CD19+ with 27% CD27+ memory B cells before culture). Values represent the mean 6 SEM of quadruplicate cultures; asterisks
indicate statistically significant differences. (G) Absolute yield of viable B-CLL cells (undivided or DIV) from representative experiments with IGHV
U-CLL 770, IGHV M-CLL 922, or normal PB B cells. Each was cultured with the indicated stimuli for 6 d before addition of calibration beads and harvest.
Bars represent mean 6 SEM values from three to four replicate cultures.
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FIGURE 3. IL-15–producing cells are present, proximal to pseudofollicles, in B-CLL–infiltrated spleens harboring apoptotic cells. Serial sections
of fixed and embedded splenic tissue from three B-CLL patients (M-CLL 967 with negative FISH and both U-CLL 1369 and 852, positive for
del17p) were stained for the B cell–specific transcription factor, PAX-5 (A, F, J, and N), proliferation marker Ki-67 (B, G, K, and O); or IL-15 (C, E,
H, L, and P). A separate section of the same tissue stained for IL-15 was stained with goat IgG control on the same slide (D, I, M, and Q). In
addition, a section of the U-CLL 967–infiltrated spleen was stained for active (cleaved) caspase-3 (Asp175), a marker for apoptotic cells (R). (E and
R) Represent higher magnification (6003) photographs of differing sections of CLL-967 from (A) to (D), whereas (J)–(M) represent enlargements of
the boxed pseudofollicle section in (F)–(I), respectively (from U-CLL 1369–infiltrated spleen). The surgical pathology report (case number: FS088095; Genzyme specimen number: 08-50886842-MH) for the M-CLL 967 spleen noted: “A markedly enlarged spleen (.2 kg) in a patient with
a history of CLL/SLL. Infiltrated lymphocytes are small to medium with round to oval to nuclear contours and inconspicuous nucleoli. Cells are
located in both white pulp and red pulp. They are positive for CD20, PAX5, CD5, CD43, Bcl-2, with kappa l.c. restriction and negative for CD10,
CD23, Bcl-1, Bcl-6, MUM-1 and T cell markers.” The pathology reports for U-CLL 1369/U-CLL 852 were not available, but it was evident that
little normal splenic architecture remained in U-CLL 852. Photographs were taken from an Olympus BX40 microscope using 103, 203 and 603
UPLanFl oil immersion objectives and an Olympus DP20 camera. The images involving thicker sections of U-CLL852 spleen were brightened to
better distinguish the specific brown staining from the very dark hematoxylin staining of nuclei.

throughout the examined white pulp, albeit the staining intensity
was diminished in the spleen with passive congestion. The 6003
image in Fig. 5A shows that IL-15 appeared localized throughout
the cytoplasm in some cells and also expressed in a perinuclear
pattern in others. Both the reports that IL-15 localization patterns
can vary in differing cell populations (66, 68, 69) and the varying
morphologies of IL-15+ cells in all the above spleens suggest that
more than one splenic population is IL-15+, but this will require
further investigation. Our finding of IL-15 expression within
normal human spleen is consistent with images found online in

the Protein Atlas (http://www.proteinatlas.org/ENSG00000164136IL15/tissue/spleen).
Taken together, the earlier immunohistochemical studies show
that IL-15–producing cells are localized within the splenic white
pulp of both B-CLL patients (3/3) and individuals without B-CLL
(2/2). In the case of the three B-CLL–infiltrated spleens, IL-15+
cells were found proximal to areas of proliferating B cells, albeit
they were not exclusive to this location. The latter findings support
the possibility that IL-15 might be providing important signals to
B-CLL cells within the patient. If findings in studies with NK cells
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FIGURE 4. FDCs colocalize with IL-15–producing cells in pseudofollicles of a B-CLL–infiltrated spleen. Serial sections of CLL-967–infiltrated spleen
harboring numerous PAX-5+ (A) and Ki-67+ (B) pseudofollicles (stained as in Fig. 3) were stained for IL-15 (D and F) or for a carbohydrate Ag unique to
human FDCs (CNA.42) (67) (C and E). A region of the spleen with clearly identifiable landmarks was selected for the visualization of these respective
molecules. (A–D) Panels represent original magnifications 3100 of the region of interest. (E and F) Panels represent original magnifications 3600 of the
boxed regions shown in (C) and (D) for FDC-specific CNA.42 and IL-15, respectively. (F) Image was hue-enhanced to convert yellow-brown stained cells to
red, which is better visualized against a background of blue nuclei.

and T cells apply to B-CLL, it is likely that IL-15 signaling in the
spleen involves highly functional, soluble IL-15Ra/IL-15 complexes (70, 71) or IL-15Ra–bound IL-15 on the surfaces of IL-15–
producing cells (72), both of which are more effective than soluble
IL-15.
Membrane CD38 rises on B-CLL cells during ODN+IL-15–
induced cycling
CD38, a type II transmembrane protein, belongs to a family of
nucleotide-metabolizing enzymes and catalyzes the conversion
of NAD+ to cyclic ADP ribose, with a resulting Ca2+ flux. It is
notably upregulated in normal germinal center B cells, plasma
cells, and several malignancies (reviewed in Ref. 73). In
B-CLL, CD38 is linked to an activated phenotype (74–76),
greater Ki-67 expression (6, 75), and typically, but not uniformly, worse patient prognosis (77–79). Very recent evidence
suggests that CD38 enzymatic function is needed for in vivo
binding to PECAM-expressing endothelial cells and CLL migration (79).

If collaborative ODN+IL-15 signaling is a driver of in vivo
B-CLL growth, one would anticipate these stimuli to upregulate
CD38. Through two-color flow cytometry of CFSE-labeled B-CLL
stained for surface CD38 after activation, we found that both CD38
expression levels and the percentage of CD38+ cells progressively
increase with increased division cycles (Fig. 6). On average, CD38
levels in cycling blasts were 1–2 logs greater than in cells exposed
to either ODN or IL-15 (Fig. 6A, 6B). Furthermore, CD38 expression rose upon division, even when the blood-isolated quiescent B-CLL population was predominantly CD38+ (U-CLL 675 =
74% positive). Even so, not all proliferating B-CLL uniformly
became CD38+, as can be seen in the case of U-CLL 430, a clone
with few CD38+ cells in blood (Fig. 6C, 6D). Taken together, we
conclude that exposure to ODN+IL-15 is sufficient for inducing
division-linked CD38 expression in B-CLL leukemic cells.
Nonetheless, expression of CD38 is not restricted to these stimuli
because it is also inducible after B-CLL stimulation by IL-2 (80),
and particularly CD40L + IL-4 (81) and autologous activated
T cells (6). In addition, and of interest, although most extensively
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FIGURE 5. IL-15–producing cells can be detected
within the white pulp of normal human spleens. Tissue
sections were derived from two human spleens (A and
B), determined to be normal upon pathological examination (see Materials and Methods). They were
stained and examined for human IL-15, as described
for Fig. 3. Cells positive for cytoplasmic IL-15 were
found scattered throughout the white pulp of each
spleen, in patterns similar to those shown in the present
images. A rim of more dense IL-15+ cells often appeared
to encircle follicles [as in the lower right panel in (A)],
suggesting possible marginal zone localization. In addition, cells with more intense IL-15 expression were
sometimes found proximal to the splenic artery [as in the
upper right panel in (A)].

DIV B-CLL blasts express CD38, intraclonal heterogeneity can
exist, leaving a fraction of cells to undergo at least three division
cycles without upregulating the surface enzyme. This latter evidence that division can proceed without the upregulation of CD38
is consistent with results of a study using 2H (deuterium)-labeled
water to monitor B-CLL divisions within patients (82). In that
study, division was detected in both CD38+ and CD382 B-CLL,
although CD38+ cells appeared to proliferate more rapidly (82).
Factors that regulate strength of the B-CLL proliferative
response to ODN+IL-15
Initial experiments to test for ODN+IL-15 synergy in promoting
B-CLL growth revealed considerable diversity between clones in
the extent of cycling. Diversity could not be simply explained
by whether the B-CLL specimen was isolated from fresh blood or
after storage in liquid nitrogen: in several B-CLL that underwent
replicate testing under both conditions, relatively minimal, if any,

interexperimental differences in viability and/or division potential
were noted (Supplemental Fig. 2). Therefore, other explanations
were investigated for the differences between B-CLL clones.
No influence of IGHV mutated/unmutated status. As indicated
earlier, IGHV mutation status is a strong predictor of B-CLL
in vivo growth (4, 5, 83): U-CLL . M-CLL. Therefore, despite
early impressions that U-CLL and M-CLL could manifest relatively similar responses to combined ODN + IL-15 signaling
(Fig. 1), it was critical to use a larger group of clones to adequately test the null hypothesis. Characteristics of the larger group
of 40 CLL (20 U-CLL and 20 M-CLL) are shown in Table I, and
a summary of our findings concerning the in vitro growth of these
clones is presented in Fig. 7A and 7B, respectively. Results are
shown in stacked bar format as absolute recovery of viable (black)
and dead (gray) cells within subpopulations gated on the basis of
division: undivided (Fig. 7, top row), total DIV (middle row), and
more than two divisions (bottom row). Individual CFSE histogram
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FIGURE 6. Membrane expression of CD38 rises in replicating blasts during ODN+IL–15-induced B-CLL clonal expansion. (A and B) Cell-surface
CD38 levels were assessed on gated viable cells at time 0 and after 3–6 d of CFSE-labeled B-CLL culture with stimulant: IL-15 only, ODN only, or both
ODN+IL-15. U-CLL 675 and U-CLL 430 represented B-CLL with relatively high and low proportions, respectively, of CD38+ cells in blood (anti-CD38 =
darker shading; IgG control = light). Both populations appear to notably upregulate CD38 expression during divisions triggered by ODN+IL-15. (C)
ODN+IL-15–stimulated U-CLL 430 cells were stained for CD38 and gated for viability and division status (on the basis of CFSE fluorescence). Histograms
represent the fluorescence intensity of CD38-stained (or IgG control-stained) cells within each division subset and show definitively that CD38 expression
rises with each incremental division. (D) Summary of experiments monitoring CD38 expression in ODN+IL-15–stimulated B-CLL cultures (n = total of 5
CLL; top panels represent % CD38+ cells in each division subset; bottom panels represent CD38 level, represented by the ratio of allophycocyanin antiCD38 fluorescence intensity/allophycocyanin-IgG control fluorescence intensity).

profiles of each B-CLL population’s response can be found in
Supplemental Fig. 3. Together, these studies showed that M-CLL
and U-CLL both exhibit significant interclonal variation in
responses. A statistical analysis of the viable or dead cell yield
within each of the division-based groups, using the Mann–Whitney
rank sum test, showed no statistically significant differences between the U-CLL and M-CLL subgroups. In addition, when
U-CLL and M-CLL cohorts were compared on the basis of percentage viability within the undivided or DIV subsets or percentage
DIV within total viable cells (criteria used in prior studies with
normal B cells) (55–57), no statistically significant difference
emerged (data not shown). Taken together, we find no evidence that
the B-CLL clone’s BCR mutation status is independently linked to
vigor of the ODN+IL-15–induced in vitro response. These findings
suggest that if adequate amounts of CpG DNA and IL-15 are found
within patient lymphoid tissues, leukemic cells from both U-CLL
and M-CLL subsets should be driven to replicate, survive, and
generate CD38+ progeny, unless otherwise suppressed or negatively regulated by other stimuli or cell interactions.
Effect of B-CLL chromosomal anomalies on the in vitro response
to ODN + IL-15. Several chromosomal anomalies are frequently
found in B-CLL: del13q14, TRI-12, del11q22, and del17p. Pos-

session of monoallelic del13q14 alone is generally, albeit not
uniformly, linked to less aggressive disease (84, 85), whereas TRI12, del11q22, and del17p more typically predict worse prognosis
(86). We hypothesized that the relative potential of a B-CLL clone
to mount a robust in vitro response to ODN+IL-15 might be linked
to expression of pathogenic anomalies in at least a fraction of the
total IGHV-determined clonal population. Because of the evidence
that p53 activation negatively affects the survival of normal replicating human B lymphoblasts (57, 87), it warrants noting that
TRI-12 increases the gene dose for Mdm2 (88), a major p53 inhibitor (89). Furthermore, del11q22 removes the gene for ATM
(90, 91), a major p53 activator after DNA damage or oxidative
stress. Deletion of 17p removes the p53 gene itself (86). Finally,
del13q14 removes miR15/16, which negatively regulate Bcl-2,
Mcl-1, and certain cell cycle proteins, as well as often removing
DLeu7, an NF-kB inhibitor (reviewed in Ref. 92).
Insights into how genetic anomalies found in our cohort (Table I)
affect the ODN+IL-15–induced response came from the data in
Fig. 8. Populations were grouped into those with: 1) no FISHdetermined anomalies (n = 15), 2) TRI-12 alone (n = 5), 3)
TRI-12 and del13q14 (n = 1), 4) del13q14 alone (n = 8), 5)
del11q22 alone (n = 5), and 6) both del11q22 (or ATM mutation)
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—
39 mo
—
—

72 mo
—
—
—
418 mo
8 mo
—
—
—
—
31 mo/chemo
8 mo/Ritux
—
—
—
—
—
—
—
—
—
—
—

.183
.522
141
.136
.128
.119
.116
.116
.115
174
.186
.115

.168
.96
.99
.96
485
.92
.90
45
75
.356
.192

140
58
58
.112
79
.77
.108
22
.68
86
128
69

.157
252
.70
.164
.79
.80
.129
.86
.61
.61
.71
.55
.111
.48
.33

78
210
54
.148
.73
.72
.77
.75
.9
1
.37
.52
.70
.46
.33

—
—

—
—

—
276 mo
12 mo

.215
.203

.193
.203

12
.62
.62
.77
0
29
25
. 36
52
.326
8

—
—

OS
(mo)

TFT
(mo)

Functional
Study:
Time from
Therapyd

b

RAI stage at the time of test sample acquisition (RAI stage at the last time the patient was clinically monitored).
Designates the results of FISH-determined chromosomal analyses. If deletions were present, the % of cells showing either heterozygous (het) or homozygous (ho) deletions is indicated in parentheses. Chromosomal defects were considered present if the anomaly was present in $5% of the cells. Although in
most cases, FISH/ATM mutation analyses were performed within 1 y of the blood sampling for later functional studies, in the case of the following B-CLL, FISH analyses were performed from 2 to 5 y before the sample for culture: CLL IDs: 321, 430, 600, 624, 887, and 950.
c
B-CLL blood had been screened for % of CD19+/CD5+ doubly stained cells in the lymphocyte (lc) population after diagnosis and generally before the time of blood sampling for B cell isolation. In some cases, single staining for CD19, CD5, and CD3 was performed; in the latter, % of
the blood lymphocyte population positive for CD19/CD5/CD3, respectively, is shown.
d
Shown is the time separation (in months) between any earlier chemotherapy and the acquisition of PB for B-CLL purification and growth experiments. Note that 84% of the B-CLL clones tested were obtained from patients prior to the beginning of therapy. Dashes indicate that B-CLL
specimens were obtained prior to any patient therapy.
chemo, chemotherapy; del, deletion; lc, lymphocytes; M, IGHV mutated; mut, mutation; nd, not determined; Neg, negative; not avail, not available; Ritux, Rituximab; U, IGHV unmutated; WT, wild-type ATM gene.

a

71
75

Age (y)

186
275

CLL Clone

IGHV
mut
Status

Table I. Clinical and biological characteristics of tumor-bearing patients and B-CLL clones
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FIGURE 7. IGHV unmutated and mutated B-CLL subsets both display notable interclonal diversity in ODN+IL-15–induced growth. CFSE-labeled (A)
U-CLL cells (n = 20) and (B) M-CLL cells (n = 18), each at 105 cells/culture, were stimulated for 6–7 d with ODN+IL-15 before harvest with standardization beads, fixation, and FACS analysis for division status and viability (as in Supplemental Figs. 1, 3). A few cultures manifesting earlier peak
division were harvested at day 5 to prevent death from nutrient deprivation. Experimental data shown represent the absolute recovery of gated viable or
dead cells within the designated categories: undivided, total DIV, or DIV with more than two divisions. The data are shown in stacked bar format for each
B-CLL clone (indicated by ID on the abscissa). (Note: M-CLL 1258 and M-CLL 1260 are not represented because experiments with the latter B-CLL did
not include standardization beads). SEM of triplicate/quadruplicate cultures was nearly always ,15% of the mean value, and most typically ,5% (as in
Fig. 1G). On rare occasions when the calculated absolute cell yield in one replicate varied .2-fold from the others, it was determined to be an outlier and
excluded. Mann–Whitney rank sum tests were performed to evaluate whether the U-CLL and M-CLL subgroups varied in their responses within any one
measurement category. No statistically significant differences were noted.

and del13q14 (n = 6). The viability of undivided and DIV B-CLL
cells after 6–7 d of culture is shown in Fig. 8A and 8B, respectively, whereas Fig. 8C–F reveals the extent of B-CLL cycling, as
represented in three diverse ways: 1) percentage DIV cells within
the total viable gate (Fig. 8C); 2) percentage of total viable DIV
cells with .2 divisions (Fig. 8D); and 3) absolute yield of viable
DIV cells per culture (Fig. 8F). The absolute yield of viable undivided cells is also shown (Fig. 8E).
Several statistical analyses were performed to discern whether
differences between B-CLL clones in each of these functional
parameters could be attributed to the FISH subgroups. An initial
Kruskal–Wallis statistical test was performed to assess whether
there was statistical variation between the five major groups (see
Fig. 8 legend). This revealed significant differences among the
subgroups in percent viability within undivided cells (Fig. 8A, p =
0.007), percent viability within DIV blasts (Fig. 8B, p = 0.0408),
percentage DIV within total viable cells (Fig. 8C, p = 0.0019), and
absolute yield of viable undivided cells (Fig. 8E, p = 0.019).
Although variation was apparent in the absolute yield of viable
DIV cells (Fig. 8F), this did not reach statistical significance
(p = 0.118). Further statistical evaluations using a Wilcoxon rank
sum test, which made pairwise comparisons of the subgroups,

delineated which genetic anomalies were linked to notably greater
viability and/or growth.
A trend toward heightened viability in undivided cells (Fig. 8A)
and DIV blasts (Fig. 8B), above that in the FISH-negative group,
was seen in B-CLL clones jointly expressing del11q22 (6 ATM
mutation) and del13q14. For both undivided and DIV cells, this
was unlikely due to chance (p = 0.016 and p = 0.009, respectively), although with a Bonferroni correction for multiple comparisons set at 0.005, these were not statistically significant.
B-CLL clones bearing both an ATM anomaly and del13q14 also
trended toward greater viability in the undivided and DIV fractions than those expressing del11q22 alone (p = 0.006 and p =
0.044, respectively; Fig. 8A).
Interestingly, B-CLL expressing only TRI-12 showed significantly greater propensity for division in response to ODN+IL-15
(Fig. 8C; p = 0.0001 for TRI-12 versus FISH2, p = 0.004 for
TRI-12 versus del11q22 (6 ATM mut) + del13q14, and p = 0.008
for TRI-12 versus del11q22 alone). No other group differed significantly from the FISH2 group in terms of percent division in
the viable-gated fraction, although joint expression of an ATM
anomaly and del13q14 appeared to favor greater division when
compared with clones with del11q22 only (p = 0.009; Fig. 8C).
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FIGURE 8. Effect of common B-CLL
genetic anomalies on survival/growth properties of ODN+IL-15–stimulated B-CLL
clones. B-CLL clones in Table I were subdivided on the basis of FISH analyses for
TRI-12, del13q14, and del11q22 (ATM).
B-CLL849 was the only TRI-12 + population additionally positive for del13q14. It
was considered independent of the group
expressing TRI-12 alone (n = 5) and not
included in any of the statistical evaluations.
*CLL770 was placed in the group with both
del13q14 and del11q22 on the basis of harboring two ATM mutations. *CLL430 possessed both del11q22 and del13q14 and
one ATM mutation. B-CLL subgroups were
compared for % viability in the (A) undivided and (B) DIV cell gates; (C) % of viable-gated cells showing evidence of division;
(D) % of DIV viable cells with more than
two divisions; (E) absolute recovery of viable, undivided cells per culture; and (F) absolute recovery of viable DIV blasts per
culture. (C and D) The responses of B-CLL
evaluated in a single experiment are shown
by bars representing the intraexperimental
mean 6 SD of triplicate cultures; values for
other B-CLL in bold (ID 346, 1300, 624,
321, 1013, 945, 1086, 940, 1328, 1380, 922,
675, 430, 887, and 770) represent the
mean 6 SD value from two to four separate
experiments with the same B-CLL. The T
atop certain bars indicates that this B-CLL
population derived from a patient who received treatment at $8 mo prior to acquisition of leukemic B cells from blood (see
Table I). The p values placed above each plot
are derived from the Kruskal–Wallis test for
differences within the multiple groups and
represent Monte Carlo estimates for the exact test. The p values within (or below) the
plots are derived from Wilcoxon rank sum
test for differences between paired groups, as
indicated in Materials and Methods.

Taken together, this analysis suggests that TRI-12 enhances the
potential for in vitro ODN+IL-15–stimulated B-CLL division,
whereas an ATM anomaly combined with del13q14 promotes
greater viability and perhaps greater division.
The frequency of FISH-determined anomalies within cells of
a clone is quite heterogenous (Table I). This diversity likely
contributes to the intraclonal differences observed in percentage viability and/or extent of cycling (e.g., in Fig. 1A and

Supplemental Fig. 3). It is additionally possible that intraclonal
variations represent inherent differences in subclonal members
that relate to differing surface membrane receptors or signaling
status, that are either fixed or temporary, for example, based on
time since last replication (93). It is unlikely that most differences
in the extent of cycling within a given B-CLL population represent contaminating nonleukemic cells, because diversity was
evidenced in cultures that were 99–100% CD19+/CD5+ before
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activation, as well as in day 5 activated cells stained positively for
CD19/CD5 (data not shown).
Effect of prior treatment on ODN+IL-15–induced in vitro B-CLL
clonal expansion. Prior therapy has been linked to the emergence of
more malignant B-CLL subclones. Because a minor proportion of
our cohort (7/40) represented leukemic cells taken from patients
with earlier treatment (8 to 418 mo prior to blood sampling;
Table I), it was deemed relevant to examine whether a more robust
ODN+IL-15 response was statistically linked to prior treatment. In
Fig. 8, those B-CLL clones taken from patients receiving earlier
treatment are represented by T above the bar delineating each
clone’s response. From the dotted line thresholds for separating
relatively high versus relatively low growth (Fig. 8C, 8D), it can
be discerned that 71% (5/7) of the B-CLL from pretreated
patients showed extensive ODN+IL-15–induced replication.
Nonetheless, there was no statistically significant linkage between
prior treatment and the assessed growth parameters using a Fisher
exact test.
Because malignancies may develop successive mutations over
time, even independent of therapy, it was additionally relevant to
examine whether sampling time after initial diagnosis affected the
propensity to proliferate in response to ODN+IL-15. From regression analyses involving either the total B-CLL cohort (n = 40)
or B-CLL segregated on the basis of FISH anomalies, we found no
definitive link between time after diagnosis and greater division in
response to ODN+IL-15 (data not shown). Further statistical
evaluations with the Fisher exact test showed that B-CLL cells
(both U-CLL and M-CLL) obtained at #50 or .50 mo postdiagnosis exhibit no significant difference in growth potential, as
discerned by percentage of total viable cells with more than two
divisions (data not shown). Thus, within the presently studied
B-CLL cohort, there was no statistical evidence that B-CLL populations taken from a late point in the disease process showed
a significantly more robust response to ODN+IL-15. Nonetheless
and importantly, this assessment may be compromised by limited
sample number. Better insights on whether in vitro growth potential is altered with time after diagnosis will require a longitudinal study of individual B-CLL populations.
Does ODN+IL-15–stimulated in vitro growth of B-CLL clones
correlate with in vivo GR in the patient?
B-CLL in vivo GR was estimated from B-CLL doubling time in
blood (see Materials and Methods). To most accurately relate
a population’s in vitro growth to its replication in vivo, we took
measurements at or near the time blood was acquired for subsequent in vitro experiments; this could be done in all but two cases
(latter = 1–2 y after sample). Nonetheless, it must be kept in mind
that other factors influence blood doubling time, for example,
rates of survival, release from lymphatic tissue, and retention in
nontissue compartments.
A regression analysis comparing in vivo GR with in vitro growth
(absolute yields of CLL lymphoblasts with more than two divisions) is shown in Fig. 9. Evaluations were made for U-CLL and
for M-CLL separately, because GRs of the latter two subsets
differ significantly (4), as confirmed in our CLL cohort (Fig. 9A).
Importantly, when in vivo GR of individual clones is compared
with respective levels of in vitro growth, very different regression
curves were obtained for the U-CLL and M-CLL subsets. Within
the M-CLL subset, there was no correlation between in vivo
GR and robustness of the ODN+IL-15–induced response (Fig.
9B, right panel). In fact, M-CLL clones with vigorous and with
weak ODN+IL-15–induced responses had equally low GR. The
latter indicates that the characteristic slow clinical progression of
M-CLL must, at least in some cases, reflect factor(s) other than
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a clone’s intrinsic ability to respond to growth-promoting stimuli.
In contrast, for U-CLL clones, there was a suggestion that in vivo
and in vitro growth are directly linked, although statistical significance was not reached (Fig. 9A, left panel).
Recent in vivo activation of B-CLL appears to compromise
ODN+IL-15–induced in vitro clonal expansion
We wished to understand why a clone’s intrinsic potential for
ODN+IL-15–stimulated growth was not in greater alignment with its
apparent growth in the patient. One possibility was that the relatively recent emergence of blood B-CLL from a proliferative
experience in tissue might be a factor influencing the robustness of
their in vitro response. Recent activation might either accelerate
(prime) responses to ODN+IL-15 or alternatively dampen them,
for example, as a result of proliferative senescence (94).
As an indicator of relatively recent in vivo proliferation, we
considered the proportion of blood leukemic cells expressing
CD38. Although blood B-CLL are uniformly small, expression of
this marker has been strongly linked to recent B-CLL growth (75,
76). B-CLL clones were subdivided into CD38high and CD38low
groups, on the basis of a 30% threshold. The latter is often used to
distinguish CLL with fast and slow clinical progression, CD38high
generally . CD38low (77, 95, 96). CD38high and CD38low subgroups were compared in box-plot format for in vivo GR (Fig. 9C)
and separately for in vitro expansion in response to ODN+IL-15
(Fig. 9D). As expected, CD38high B-CLL had a median in vivo GR
that was 2.5-fold greater than CD38low B-CLL (Fig. 9C), although
the difference did not reach statistical significance, likely because
of limiting cohort size. Unexpectedly and to the contrary, extended
in vitro growth in ODN+IL-15–stimulated CD38high clones was
39% of that seen with CD38low clones (Fig. 9D). This trend for
CD38high clones to proliferate less vigorously than CD38low
clones was seen in both U-CLL and M-CLL subsets, although as
expected with diminished sample size, statistical significance was
not reached (data not shown).
Based on the above insight, we re-examined whether a direct
relationship exists between in vitro and in vivo growth using only
CD38low U-CLL clones. The U-CLL clones were of particular
interest because we envisioned that the BCR specificity of this
group makes it less likely that limited access to stimuli will be
a critical factor controlling in vivo growth. Unlike the more restricted BCR specificities of M-CLL clones, U-CLL exhibit polyreactive BCR that can bind several self-Ags, including many
expressed on stressed and apoptotic cell membranes (19–21, 28).
Interestingly, with this approach, a statistically significant link was
found between GR in the patient and ODN+IL-15–triggered
growth (p = 0.046; Fig. 9E). When the CD38high U-CLL subset
was considered, no such relationship was apparent (data not
shown). Rather, a clone (CLL 1331) with the most rapid in vivo
GR (0.3337), and the correspondingly highest percentage CD38+
cells in blood (100%), showed negligible growth in response to
ODN+IL-15 (yield of 2410 blasts with .2 divisions).
The latter two observations prompted us to examine whether
having a very high proportion of CD38+ cells might compromise
a U-CLL clone’s in vitro response to ODN+IL-15. Indeed, when
clones with evidence of recent activation history were examined
(those .30% CD38+), a highly significant inverse relationship
was found between the percent of CD38+ cells and B-CLL in vitro
growth (p , 0.001; Fig. 8F). Parenthetically, when M-CLL were
similarly examined, four of five (80%) of the CD38high clones
were very poor responders (data not shown).
Taken together, the earlier CD38-based assessments suggest that
if the U-CLL blood population possesses relatively few CD38+
cells (due to either a substantial interval between the last prolif-
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FIGURE 9. B-CLL intrinsic potential for ODN+IL-15–induced growth versus in vivo GR and expression of CD38+ cells in blood. (A) The in vivo GR of U-CLL
(n = 16) and M-CLL (n = 20) clones are compared in box-plot format; they were statistically different (p = 0.03). These clones represent those from which serial blood
lymphocyte counts at or near the time of blood acquisition for functional study were available. (B) Potential for in vitro clonal expansion, as indicated by the absolute
yield of total lymphoblasts (viable + dead) in ODN+IL-15–stimulated cultures (y-axis) was compared with the in vivo B-CLL GR (x-axis), calculated from the
lymphocyte doubling time in blood (see Materials and Methods). No statistically significant relationship was observed, although the suggestion of a positive relationship was seen in some U-CLL clones. (C and D) B-CLL clones, whose blood leukemic cells had been assayed for CD38 expression at or near the time of blood
acquisition for these studies, were subdivided into CD38high and CD38low subsets and compared for (C) in vivo GR and (D) ODN+IL-15–induced in vitro clonal
expansion. These comparisons show a trend (albeit not of statistical significance) for CD38high B-CLL to show greater in vivo GR and lesser in vitro growth, as
compared with CD38low B-CLL. We note that when the total CLL cohort was first subdivided into U-CLL and M-CLL subsets and then examined in a similar manner,
similar trends were observed: 1) in vivo GR: for U-CLL, medians = 0.025 and 0.063 for CD38low and CD38high, respectively; for M-CLL, medians = 0.018 and 0.027,
respectively; and 2) in vitro yield of highly DIV cells: for U-CLL, medians = 119,400 and 68,900 for CD38low and CD38high, respectively; for M-CLL, medians =
137,000 and 37,200, respectively. No statistical significance was reached with the limiting sample size. (E) Regression analysis showing the relationship between in vitro
and in vivo growth within CD38low U-CLL. A statistically significant relationship was seen (p = 0.046). (F) Regression analysis showing the relationship between
absolute frequency of CD38+ cells within CD38high U-CLL and ODN+IL-15–induced clonal expansion. A highly significant inverse relationship was found (p , 0.001).

erative burst or poor CD38 upregulation during recent cycling),
then the leukemic population’s in vitro growth response to
ODN+IL-15 is a good indicator of the U-CLL clone’s overall GR in
the patient. In contrast, if most blood leukemic cells represent CD38+

progeny of a relatively recent proliferative burst, then they are
compromised in responding to ODN+IL-15 with a new burst of
growth. The reasons for these differences can presently only be
speculated (see Discussion) and will require further study.
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Impact of genetic anomalies on in vitro growth of CD38high and
CD38low U-CLL
Although our cohort size is too limited to undertake a multivariate
statistical analysis, we believe some discussion of the distribution
of chromosomal anomalies in the CD38low and CD38high subsets is
warranted. The earlier analysis in Fig. 8 showed that a robust
B-CLL response to ODN+IL-15 is linked to TRI-12 and to the
combination of del11q22 + del13q14. Therefore, it was possible
that these anomalies mitigate the negative influences of elevated
CD38 expression on ODN+IL-15–induced cycling.
When the CD38low U-CLL subgroup in Fig. 9E was inspected
for FISH anomalies, we found that 80% of those clones with
strong in vitro growth possessed either TRI-12 or both del11q22
(or ATM mutations) and del13q14. The latter clones (CLL 1692,
430, 770, 950, and 887) are represented by the black circles on or
above the regression line. Only 25% (1/4) of this subgroup’s
members with poor in vitro growth possessed these anomalies.
The earlier findings substantiate the link between vigor of the
in vitro response and these genetic anomalies. Importantly, they
also indicate that expression of these anomalies within a clone is
not uniformly linked to high levels of CD38+ cells in blood.
Within the CD38high U-CLL subgroup (plot not shown), 75% (3/
4) of the clones with the greatest in vitro growth (81–182 3 103
blasts with more than two divisions) expressed either TRI-12 or
the combination of deletions in 11q11 and 13q14 (CLL 1013, 675,
1081). This contrasted with this subgroup’s clones manifesting the
weakest in vitro growth (0.02–31 3 103 blasts .2 divisions) (CLL
631, 529, 1238, 625, and 1331). Of interest, 80% (4/5) of the latter
expressed del11q22 alone, without accompanying del13q14, in
70–100% of the blood leukemic cells (Table I), as well as a very
elevated frequency of blood CD38+ cells (mean 6 SD = 82 6
11% positive). The possibility that TRI-12 or combined deletions
in 11q and 13q override the negative influences of CD38 will need
to be examined through future FISH analyses of leukemic blasts
sorted on the basis of CFSE expression. Nonetheless, there are
strong indications that CD38+ B-CLL bearing del11q22 alone are
compromised in their in vitro growth to ODN+IL-15.
Comparison of in vitro viability/growth characteristics of
ODN+IL-15–stimulated B-CLL clones with clinical
progression in patients
The best evidence to date that in vivo leukemic cell birth rate is
linked to disease activity comes from experiments that measured
leukemic cell uptake of deuterium in patients drinking heavy
water (4, 83). Prompted by the strong suggestions that IL-15
and ODN signaling could contribute to pseudofollicle growth,
we examined whether a clone’s intrinsic potential for in vitro
ODN+IL-15–induced clonal expansion correlates with the patient’s
disease progression. Kaplan–Meier plots, with accompanying logrank statistical evaluations, were used to assess whether TFT or
OS of the patient is linked to the B-CLL clone’s high-proliferator
versus low-proliferator status in vitro. Of note, CD38high B-CLL
with compromised in vitro growth were not excluded from these
analyses because of the need to retain a relatively large sample
size.
In Fig. 10, we compare the clinical outcome of the full CLL
cohort, and segregated U-CLL and M-CLL subsets, with the frequency of highly DIV viable blasts in ODN+IL-15–stimulated
cultures. Both TFT (Fig. 10A) and OS (Fig. 10B) were considered.
The Kaplan–Meier plots reveal no statistically significant TFT
difference within patients harboring high- versus low-proliferating
clones for the full B-CLL cohort or its U-CLL or M-CLL subsets
(Fig. 10A). Nonetheless, significantly worse OS was noted in
patients with high-proliferator clones, when the full cohort of CLL
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was assessed (p = 0.015; Fig. 10B, left plot). Separation of the full
cohort into its U-CLL and M-CLL components suggests that accelerated patient death associated with high-proliferating clones is
a characteristic of U-CLL and not M-CLL, even though statistical significance was not reached in the case of U-CLL clones
(p = 0.083). A lack of statistical significance for the U-CLL
comparison likely reflects reduced sample size (n = 20 versus
n = 40 for the full cohort). This conclusion is supported by a significant difference in OS values for high- versus low-proliferator
U-CLL clones (p = 0.04), when a slightly different discrimination
threshold was used (#75% or .75% DIV within total viable
cells). Furthermore, high and low proliferators in the M-CLL
subset showed no significant difference with either threshold
(p = 1.000).

Discussion
Despite their blood manifestation as relatively quiescent lymphocytes,
a fraction of each B-CLL clone undergoes significant proliferation
in the patient, associated with varying degrees of clonal contraction
(4, 5). Bursts of proliferation within lymphoid tissue pseudofollicles are linked to clinical progression (11, 97), and this continues to elicit interest in defining the mechanisms for localized
B-CLL growth. We report for the first time, to our knowledge, that
two stimuli, which are likely present in all primary and secondary
lymphoid tissues, display notable synergy in promoting in vitro
B-CLL cycling. In lymphoid tissues, CpG DNA could be available
from apoptotic cells/debris and/or microbes (98–102), and IL-15
is anticipated from stromal cells, dendritic cells, and macrophages
(43–45). In support of the above, to our knowledge, this study
provides the first immunohistochemical evidence that apoptotic
cells and IL-15–producing cells are present in B-CLL–infiltrated
spleens. Our in vitro functional experiments with CFSE-labeled
B-CLL show that significant ODN+IL-15–induced growth can be
elicited from both IGHV-unmutated and IGHV-mutated B-CLL
subsets, the latter of which is characteristically vulnerable to apoptosis upon exposure to CpG DNA alone (35, 37, 40, and this
report). The novel evidence for CpG DNA + IL-15 synergy in
promoting B-CLL growth is in harmony with past findings that
normal human memory B cells cycle extensively in response to
CpG and IL-15 (49) and further evidence that B-CLL cells manifest gene expression profiles resembling memory B cells (50). In
addition, our observations are consistent with evidence that both
U-CLL and M-CLL manifest high levels of TLR-9 (35, 39) and
that B-CLL express high- and low-affinity receptors for IL-15 (51,
52). IL-15 is best recognized as a growth-promoting cytokine for
cells involved in immune surveillance: NK cells and CD8 cytotoxic cells (73, 103). In the case of patients with B-CLL, the
malignant clone could usurp IL-15 for its own expansion (schematic in Fig. 11).
The intracellular mechanisms responsible for the synergy between CpG ODN and IL-15 in eliciting B-CLL growth are presently under investigation. Nonetheless, important insights can be
derived from past investigations. M-CLL clones, predisposed to
apoptosis after early TLR-9 activation (104), show weaker ODNinduced activation of Akt and MAPKs (ERK, JNK, and p38) than
do U-CLL clones characterized by more sustained viability (35).
Other observations that treatment of B-CLL with IL-15 induces
phosphorylation of ERK1/2 (52) and AKT (R. Gupta and
P. Mongini, manuscript in preparation) suggest that IL-15 signals
might compensate for this poor ODN-induced signaling. In addition, because a TLR-9→NF-kB→IL-10→Stat1 pathway can
trigger ODN-induced B-CLL apoptosis (38), it is likely relevant
that IL-15 promotes the upregulation of several survival molecules, Bcl-2, Bcl-x, and Mcl-1, in other cell lineages (47, 105,
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FIGURE 10. In vitro high-proliferator status of U-CLL, but not M-CLL, is statistically linked to overall patient survival. The 40 B-CLL clones tested
for in vitro clonal expansion in response to ODN+IL-15 were analyzed for clinical progression using (A) TFT and (B) OS as indicators. The total cohort and
U-CLL and M-CLL subsets were each subdivided into high-proliferator clones (.50% of total viable cells with more than two DIV) or low-proliferator
clones (#50% of total with more than two DIV). For OS, the differing groups were distributed in the following manner: total B-CLL: low = 21 censored, 1
death; high = 13 censored, 5 deaths; U-CLL: low = 10 censored, 0 deaths; high = 5 censored, 5 deaths; M-CLL: low = 11 censored, 1 death; high = 8
censored, 0 deaths. The U-CLL populations with diminished OS included CLL 1013 (TRI-12), CLL 430 (del11q22 + del13q14 + ATM mutation), CLL 675
(del11q22 + del13q14), CLL 1158 (del11q22 + del13q14), and CLL 996 (negative for tested FISH anomalies). Kaplan–Meier analysis was performed to
discern whether the high-proliferator subgroup significantly differed from the low-proliferator subgroup regarding TFT or OS. No significant difference
between subgroups was noted for TFT. Nonetheless, patients with high proliferator clones (total cohort and U-CLL cohort) appeared to have shortened OS
as compared with those that did not (p = 0.015 for total clones was statistically significant; p = 0.083 for U-CLL clones approached significance). There was
no significant difference in the OS of M-CLL clones with high- or low-proliferator status (p = 1.00).

106). Furthermore, in CD8 T cells, IL-15 promotes increases in
c-Myc (107) and telomerase (108), two molecules linked to in vivo
B-CLL pseudofollicle growth (11, 109, 110). An IL-15–related
cytokine, IL-2, augments CLL responses to ODN (41, 104)
through a mechanism involving the heightened expression of
cyclin D2, D3, and cyclin-dependent kinase, cdk4 (41). Given that
both IL-15 and IL-2 signaling involves the shared IL-2/IL-15R
b2 (CD122) and common g (CD132)-chains (72), IL-15–promoted growth might involve similarly modulated cell-cycle proteins. Nonetheless, we find that IL-15 is superior to IL-2 in both
functioning at lower doses and yielding more robust responses
than IL-2 in ODN-triggered B-CLL cultures (R. Gupta and
P. Mongini, manuscript in preparation).
An important discovery was that spleens of B-CLL patients
possess IL-15–producing cells scattered throughout the B-CLL–
infiltrated white pulp. Through examining serial tissue sections,
we detected cells with cytoplasmic IL-15 located proximal to and
often within B-CLL pseudofollicles bearing Ki-67+ cells. This
suggests an in vivo role for IL-15 in promoting B-CLL growth.
Our additional finding that two normal human spleens also possessed IL-15+ cells scattered throughout the white pulp is quite
consistent with the recent findings of Cui et al. (44) in mouse
spleen. Using novel IL-15 reporter mice, the latter investigators
found the IL-15 promoter is active within nonlymphoid cells of
normal spleens; this was particularly noted in VCAM-1+ stromal
cells, where reporter expression increased as mice aged (44). In

our studies, some of the splenic IL-15+ cells possessed an elongated appearance, consistent with past reports of IL-15+ myofibroblasts (111), dendritic cells (43), and endothelial cells (46, 112,
113) within lymphoid tissues. Other IL-15–producing cells might
represent macrophages (114, 115), but further studies are needed
for their identification.
Numerous studies have shown that nurse cells within the
stroma of lymphoid tissue play critical roles in promoting B-CLL
survival and growth (reviewed in Ref. 116). Stromal cell lines are
often used to provide such prosurvival signals in vitro. In a set of
recent experiments, not detailed in this article, we examined
whether IL-15 was expressed and functional in HS-5 cells, a human bone marrow–derived stromal cell line with known prosurvival effects on B-CLL cells (117, 118). Using a commercial
ELISA kit for human IL-15, we found that HS-5 culture supernatants contained low but significant levels of IL-15 (611 6 163
pg/ml in three separate lots). Furthermore, an IL-15 neutralizing
Ab significantly reduced B-CLL viability in cultures containing
U-CLL (n = 2) and irradiated HS-5 cells (20:1 ratio) (R. Gupta and
P. Mongini, unpublished observations). Thus, at least some stromal cell lines with nurse activity do produce functional IL-15.
Although in vivo B-CLL growth is primarily localized in primary
and secondary lymphoid tissues, the lungs and skin of B-CLL
patients often show atypical B-CLL infiltration. It may be important that the latter are locales where IL-15 levels rapidly increase postinfection. Within lungs, IL-15 is produced in alveolar
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FIGURE 11. Schematic illustrating hypothesized role for TLR and IL15 signaling and genomic aberrations that mitigate p53 axis function for
B-CLL growth within lymphoid tissue pseudofollicles. Synergy between
CpG DNA from microbes and/or apoptotic cells and IL-15 bound to
membranes of IL-15–producing cells (43, 103) and/or in the form of
cleaved IL-15Ra/IL-15 complexes (71) may constitute an important external stimulus for promoting the growth of B-CLL leukemic cells within
tissue pseudofollicles. B-CLL clonal expansion is likely strongly influenced by factors intrinsic to the leukemic cells themselves, for example,
presence of genomic aberrations that counteract activation-linked, lymphocyte apoptosis and cell-cycle control. In addition, interactions with
PECAM-expressing endothelial cells may protect recently proliferated
CD38high cells from functional senescence and/or help sustain their survival (150).

macrophages and epithelial cells as a sequel to influenza and
pneumococcal infections (119–121). High-affinity IL-15 binding
to IL-15Ra on the membranes of all IL-15–producing cells (Kd =
10211 M) (122) makes lungs particularly effective reservoirs for
IL-15 (103). In the context our study’s findings, one might suspect
that a combined surge in levels of both IL-15 and CpG DNA,
for example, from microbes and apoptotic netting neutrophils,
during lung infections could provoke ectopic B-CLL growth. Indeed, a statistical link between development of B-CLL and earlier
pneumococcal lung infections has been reported (123). Possibly,
synergy between TLR-9 and IL-15 signaling in pulmonary tissue
explains why ∼30% of B-CLL patients show lung parenchymal
infiltration with leukemic cells upon autopsy (124). Within skin,
IL-15 levels have been elevated in Langerhans cells and keratinocytes after several routes of stimulation, including viral infection (125–127). Although speculative, synergy between TLR-9 (or
related TLR) and this cytokine might contribute to the occasional
emergence of skin-localized B-CLL follicles (124, 128, 129) at
sites of mosquito bites and former herpes simplex or zoster lesions
(130, 131).
Despite the uniform evidence of IL-15 and CpG DNA synergy,
quite importantly, we also noted substantial diversity between
individual B-CLL clones in the vigor of the ODN+IL-15–induced
response. Through a systematic comparison of the leukemic
populations for several parameters—IGHV mutation status,
common B-CLL chromosomal anomalies, and recent in vivo
proliferative history—we gained insights into the basis for this
diversity and, correspondingly, factors important in regulating
B-CLL clonal expansion.
First, we found that IGHV mutation status has no obvious effect
on a leukemic population’s intrinsic responsiveness to CpG DNA
and IL-15. Both U-CLL and M-CLL subsets contained individual
clones that were either weak or strong responders. We believe it is
important to emphasize that these findings are not in opposition
to findings that U-CLL and M-CLL exhibit very different GRs
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in vivo (5, 77, 95). Rather, examples of robust in vitro proliferation
in M-CLL clones with slow in vivo GRs support the notion that
the availability of stimulatory signals within the in vivo milieu
may be as relevant as a malignant cell’s intrinsic potential for cellcycle turnover in regulating clinically relevant growth. In particular, the more highly specific BCRs of M-CLL (26–28) make it
likely that the latter subset less frequently internalizes Ag-linked
TLR ligand (e.g., CpG DNA) than the U-CLL subset, whose BCR
are polyreactive and bind with low affinity to numerous Ags exposed on apoptotic/stressed cells (19–21). This interpretation is
consistent with evidence that apoptotic cells/debris express surface CpG DNA (19, 22) and that the latter can foster the activation
of normal B cells with low BCR affinity for self-Ags (32, 132). It
is also consistent with gene array studies showing that the TLR-9
pathway is activated within B-CLL pseudofollicles (11).
A robust B-CLL response to ODN+IL-15 was statistically
linked to the presence of chromosomal anomalies often found in
B-CLL (133): TRI-12 alone or, alternatively, del11q22 (or ATM
mutation) together with del13q14. These observations are consistent with past clinical evidence that TRI-12, del11q22, and
ATM mutations are linked to bulky disease (significant lymphadenopathy; splenomegaly) and/or elevated leukemic blood
counts, and worse patient prognosis (134–136). Nonetheless, they
add an important dimension in providing more direct evidence that
genetic anomalies influence the intrinsic potential of B-CLL
cells to survive/expand. Although a link between the latter and
OS might be expected, this is not necessarily the case and needs
experimental support. Attributes other than the malignant cell’s
intrinsic growth potential could influence patient survival. These
include communications between B-CLL cells and their milieu
(stroma, T cells, etc.) that affect leukemic cell survival, prevent
immune rejection of the B-CLL, and block the development of
normal hematopoietic cells.
We found that TRI-12 alone was linked to greater division
potential, but not heightened viability of dividing blasts. Given the
strong link between proliferation and mutagenesis, the greater
replication seen in TRI-12+ B-CLL is consistent with the suggestion that TRI-12 is a driver mutation that facilitates the accrual
of further downstream mutations (33). Heightened growth of TRI12+ clones is also in agreement with recent findings that TRI-12+
B-CLL express elevated CD38 in blood (137). Interestingly, two
recent studies found B-CLL with TRI-12 (or del11q22+) to express elevated levels of insulin growth factor receptor 1 (138,
139). The latter has pathobiological implications for B-CLL (140)
and might additionally contribute to the heightened growth within
our in vitro cultures with supplementary insulin (Materials and
Methods).
In contrast with TRI-12, combined expression of an ATM
anomaly (del11q22 6 ATM mutation) with del13q14 significantly
improved the viability of cycling B-CLL. Although these combined anomalies also appeared to favor relatively robust division,
this was below statistical significance. It was intriguing to find that
B-CLL clones with del11q22 alone showed significantly lesser
viability/growth than did clones with deletions in both 11q22 and
13q14. Given the numerous roles for ATM during cellular stress
(91), it is possible that the consequences of a 13q14 deletion might
be of particular advantage to leukemic cells with compromised
ATM function. Providing some support to the latter is evidence
from a past clinical study of B-CLL from untreated patients.
Despite the fact that the cohort under study was composed of
a greater number of clones with TRI-12 than with del11q, deletion
of 13q was more frequently found together with del11q (141).
In addition, the same study’s assessment of clonal evolution, by
sequential FISH analyses of B-CLL populations, revealed one
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del13q+ clone that later acquired del11q+, and conversely, one
del11q+ clone that later acquired del13q (141).
How might TRI-12 or ATM deletion/mutation directly influence
B-CLL viability/growth during clonal expansion? The genes responsible for heightened in vivo pathogenesis of TRI-12+ B-CLL
clones are poorly defined. Nonetheless, a past gene array analysis
showed E2F1, BAX, P27, and CDK4 to be consistently overexpressed in TRI-12+ clones (86), with only two of these (CDK4 and
P27) explained by a gene dosage effect (86). The study’s investigators suggested that the noted aberrations were most consistent
with TRI-12 potentiating the proliferation of affected B-CLL (86).
Our findings support this. Surprisingly, in the former study, cyclin
D2 and Mdm2 (both encoded on Chr12) were not elevated when
compared with other B-CLL (86). Nonetheless, because most
B-CLL clones overexpress the latter two proteins (142, 143), it
needs to be considered that distinct B-CLL use differing mechanisms for boosting the expression of these important genes, and
that the gene dosage effect of TRI-12 on cyclin D2 and Mdm2
may have been missed.
Some insight into why TRI-12 and del11q22 aberrations are
positively selected within leukemic clones can be gleaned from the
evidence that an activated p53 axis plays an important role in
curtailing the viability/growth of normal dividing B lymphoblasts,
particularly in the absence of T cell help (57, 87). Levels of p53
protein are known to increase upon DNA damage and cell stress,
resulting in cell-cycle blocks, impaired glycolytic metabolism,
and/or apoptosis (57, 144, 145). TRI-12 and del11q22 likely
compromise the p53 axis in diverse ways. Mdm2, whose gene
dose is increased by TRI-12, is ubiquitinase with a major role in
reducing p53 protein levels. Conversely, ATM, the major gene
downregulated in del11q22+ B-CLL (86), is a kinase with a critical role in stabilizing p53 protein after DNA damage or oxidative
stress (91).
During our investigations, we unexpectedly discovered that
ODN+IL-15–induced in vitro clonal expansion was impaired if
the blood B-CLL population showed signs suggestive of recent
proliferative history (high proportion of CD38+ cells). One possible explanation centers on the hypothesis that these in vitro
cultures are deficient in providing the critical signals needed for
prolonged survival and/or a new burst of growth in this population.
In vivo, there is strong evidence that CD38 promotes B-CLL
migration and survival through binding its endothelial cell–
expressed ligand, PECAM (CD31) (146) (Fig. 11 schematic).
Furthermore, there is in vitro evidence that isolated CD38high B
lineage cells are vulnerable to apoptosis. Upon BCR cross-linking,
CD38high B-CLL isolated from blood show a significant increase
in iCa2+ followed by rapid apoptosis, whereas CD38low B-CLL do
not (147). In addition, isolated nonmalignant CD38high germinal
center cells undergo rapid apoptosis in vitro (148), unless treated
by an agonist anti-CD38 mAb that elevates Bcl-2 levels (149). An
alternative hypothesis is that CD38high cells taken from blood
are either permanently and/or temporarily compromised in their
growth potential. Additional studies are needed to examine these
possibilities. To date, a clear correlation between ODN+IL-15–
stimulated culture viability and the CD38high versus CD38low status
of B-CLL taken from blood has not yet emerged (P. Mongini,
unpublished observations).
A final observation within this study that merits discussion is that
a U-CLL clone’s high-proliferator status to ODN+IL-15 stimulation was statistically linked to clinical progression. This was
evidenced by both a direct link between in vitro growth and worse
OS and a direct link between in vitro growth and in vivo GR (as
determined by doubling time in blood). The latter association, but
not the former, required that CD38high U-CLL populations be
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excluded from analysis. Although this appears to be inconsistent,
there is a possible explanation that integrates both the failure to
see an association of in vitro growth and TFT and the need to
exclude CD38high clones for evidencing a link between in vitro
and in vivo growth. This explanation is based on the strong
indications that CD38high status in blood reflects in vivo B-CLL
clonal expansion within tissues at the time of the analysis (75, 82),
as well as the fact that many CD38high clones in our cohort
prompted patient therapy after our blood sampling. It is possible
that some of the same properties of CD38high clones that contributed to their refractoriness to in vitro stimuli also fostered
greater in vivo responsiveness to treatment. The latter would
mean that CD38high clones with impaired in vitro growth would
score as having prolonged patient survival. An alternative hypothesis is that the CD38high status of certain monitored clones was only
temporary and did not represent sustained growth in the patient.
Both of these speculations are consistent with findings that high
levels of blood CD38+ cells are not uniformly a sign of poor patient
outcome (150).
Our study’s discovery of synergy between TLR-9 and IL-15
signaling pathways in eliciting B-CLL clonal expansion provides a new perspective on what may trigger pseudofollicle
growth in vivo. The hypothesized pathway, illustrated in Fig. 11, is
supported by several lines of evidence. B-CLL express both relatively high levels of TLR-9 and high- and low-affinity receptors
for IL-15. Furthermore, TLR-9 ligands, in the form of microbial
DNA or DNA from apoptotic cells, are very likely present within
tissues where B-CLL cells multiply, and internalization of these
ligands will be facilitated by the characteristic BCR specificities
of both U-CLL and M-CLL. In addition, IL-15–producing cells
appear to be intrinsic to all normal tissues where B-CLL growth is
centered and, as shown here, are detectable near or within B-CLL
pseudofollicles in patient spleens. Finally and importantly, IL-15
can convert a suboptimal TLR-9–induced stimulus into a strong
signal for B-CLL clonal expansion.
During numerous cycles of proliferation, new mutations can be
generated through oxidation, enzymatic activity of activation-induced cytosine deaminase, and/or chemotherapy, even in normal
human B cells (151). Thus, it is expected that a B-CLL population’s greater intrinsic potential for growth, facilitated by certain common chromosomal anomalies, will promote the continued
generation of further pathogenic variants. Certainly, finding ways
to curb B-CLL growth cycles within lymphoid tissues is critical.
Inhibitors of IL-15 signaling are being developed as therapeutics
for other disorders and these might be efficacious in B-CLL,
particularly in association with inhibitors of TLR-9 and BCR
signaling pathways. In the context of this study’s observations, it is
perhaps surprising that infusion therapy with either ODN alone
(38) or IL-15 alone (152) has been advocated as a treatment for
B-CLL. Because of the likelihood that synergistic IL-15 and
ODN signaling in vivo may promote B-CLL clonal expansion, we
suggest that these approaches might not be appropriate.
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128. Cerroni, L., P. Zenahlik, G. Höfler, S. Kaddu, J. Smolle, and H. Kerl. 1996. Specific
cutaneous infiltrates of B-cell chronic lymphocytic leukemia: a clinicopathologic
and prognostic study of 42 patients. Am. J. Surg. Pathol. 20: 1000–1010.
129. Robak, E., and T. Robak. 2007. Skin lesions in chronic lymphocytic leukemia.
Leuk. Lymphoma 48: 855–865.
130. Cerroni, L., P. Zenahlik, and H. Kerl. 1995. Specific cutaneous infiltrates of Bcell chronic lymphocytic leukemia arising at the site of herpes zoster and herpes
simplex scars. Cancer 76: 26–31.
131. Bairey, O., N. Goldschmidt, R. Ruchlemer, T. Tadmor, N. Rahimi-Levene,
M. Yuklea, L. Shvidel, A. Berrebi, A. Polliack, and Y. Herishanu, Israeli
Chronic Lymphocytic Leukemia Study Group (ICLLSG). 2012. Insect-bite-like
reaction in patients with chronic lymphocytic leukemia: a study from the Israeli
Chronic Lymphocytic Leukemia Study Group. Eur. J. Haematol. 89: 491–496.
132. Avalos, A. M., L. Busconi, and A. Marshak-Rothstein. 2010. Regulation of
autoreactive B cell responses to endogenous TLR ligands. Autoimmunity 43:
76–83.
133. Puiggros, A., G. Blanco, and B. Espinet. 2014. Genetic abnormalities in chronic
lymphocytic leukemia: where we are and where we go. Biomed. Res. Int. 2014:
435983.
134. Matutes, E., D. Oscier, J. Garcia-Marco, J. Ellis, A. Copplestone,
R. Gillingham, T. Hamblin, D. Lens, G. J. Swansbury, and D. Catovsky. 1996.
Trisomy 12 defines a group of CLL with atypical morphology: correlation
between cytogenetic, clinical and laboratory features in 544 patients. Br. J.
Haematol. 92: 382–388.
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chronic lymphocytic leukemia: a comprehensive review. Blood Rev. 23: 25–47.
137. Riches, J. C., C. J. O’Donovan, S. J. Kingdon, F. McClanahan, A. J. Clear,
D. S. Neuberg, L. Werner, C. M. Croce, A. G. Ramsay, L. Z. Rassenti, et al.
2014. Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of
integrin signaling that is modulated by NOTCH1 mutations. Blood 123: 4101–
4110.
138. Maura, F., L. Mosca, S. Fabris, G. Cutrona, S. Matis, M. Lionetti, L. Agnelli,
M. Barbieri, M. D’Anca, M. Manzoni, et al. 2015. Insulin growth factor 1 receptor expression is associated with NOTCH1 mutation, trisomy 12 and aggressive clinical course in chronic lymphocytic leukaemia. PLoS ONE 10: e0118801.
€
139. Yaktapour, N., R. Ubelhart,
J. Sch€uler, K. Aumann, C. Dierks, M. Burger,
D. Pfeifer, H. Jumaa, H. Veelken, T. Brummer, and K. Zirlik. 2013. Insulin-like
growth factor-1 receptor (IGF1R) as a novel target in chronic lymphocytic
leukemia. Blood 122: 1621–1633.
140. Saiya-Cork, K., R. Collins, B. Parkin, P. Ouillette, E. Kuizon, L. Kujawski,
H. Erba, E. Campagnaro, K. Shedden, M. Kaminski, and S. N. Malek. 2011. A
pathobiological role of the insulin receptor in chronic lymphocytic leukemia.
Clin. Cancer Res. 17: 2679–2692.
141. Shanafelt, T. D., T. E. Witzig, S. R. Fink, R. B. Jenkins, S. F. Paternoster,
S. A. Smoley, K. J. Stockero, D. M. Nast, H. C. Flynn, R. C. Tschumper, et al.

The Journal of Immunology

142.

143.

144.
145.
146.

147.

2006. Prospective evaluation of clonal evolution during long-term follow-up of
patients with untreated early-stage chronic lymphocytic leukemia. J. Clin.
Oncol. 24: 4634–4641.
Delmer, A., F. Ajchenbaum-Cymbalista, R. Tang, S. Ramond, A. M. Faussat,
J. P. Marie, and R. Zittoun. 1995. Overexpression of cyclin D2 in chronic B-cell
malignancies. Blood 85: 2870–2876.
Watanabe, T., T. Hotta, A. Ichikawa, T. Kinoshita, H. Nagai, T. Uchida,
T. Murate, and H. Saito. 1994. The MDM2 oncogene overexpression in chronic
lymphocytic leukemia and low-grade lymphoma of B-cell origin. Blood 84:
3158–3165.
Efeyan, A., and M. Serrano. 2007. p53: guardian of the genome and policeman
of the oncogenes. Cell Cycle 6: 1006–1010.
Maddocks, O. D., and K. H. Vousden. 2011. Metabolic regulation by p53. J.
Mol. Med. 89: 237–245.
Vaisitti, T., V. Audrito, S. Serra, R. Buonincontri, G. Sociali, E. Mannino,
A. Pagnani, A. Zucchetto, E. Tissino, C. Vitale, et al. 2015. The enzymatic
activities of CD38 enhance CLL growth and trafficking: implications for
therapeutic targeting. Leukemia 29: 356–368.
Zupo, S., L. Isnardi, M. Megna, R. Massara, F. Malavasi, M. Dono, E. Cosulich,
and M. Ferrarini. 1996. CD38 expression distinguishes two groups of B-cell

923

148.

149.

150.

151.

152.

chronic lymphocytic leukemias with different responses to anti-IgM antibodies
and propensity to apoptosis. Blood 88: 1365–1374.
Lebecque, S., O. de Bouteiller, C. Arpin, J. Banchereau, and Y. J. Liu. 1997.
Germinal center founder cells display propensity for apoptosis before onset of
somatic mutation. J. Exp. Med. 185: 563–571.
Zupo, S., E. Rugari, M. Dono, G. Taborelli, F. Malavasi, and M. Ferrarini. 1994.
CD38 signaling by agonistic monoclonal antibody prevents apoptosis of human
germinal center B cells. Eur. J. Immunol. 24: 1218–1222.
Malavasi, F., S. Deaglio, R. Damle, G. Cutrona, M. Ferrarini, and N. Chiorazzi.
2011. CD38 and chronic lymphocytic leukemia: a decade later. Blood 118:
3470–3478.
Haque, S., X. J. Yan, L. Rosen, S. McCormick, N. Chiorazzi, and
P. K. Mongini. 2014. Effects of prostaglandin E2 on p53 mRNA transcription
and p53 mutagenesis during T-cell-independent human B-cell clonal expansion.
FASEB J. 28: 627–643.
Laprevotte, E., G. Voisin, L. Ysebaert, C. Klein, C. Daugrois, G. Laurent,
J. J. Fournie, and A. Quillet-Mary. 2013. Recombinant human IL-15 transpresentation by B leukemic cells from chronic lymphocytic leukemia induces
autologous NK cell proliferation leading to improved anti-CD20 immunotherapy. J. Immunol. 191: 3634–3640.

